Compare stocks

ATRA vs CING

Atara Biotherapeutics, Inc and Cingulate Inc. Common Stock

Compare the businesses

Atara Biotherapeutics, Inc

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Open ATRA dashboard ↗

Cingulate Inc. Common Stock

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

Open CING dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

New to NexusTrade? Create a free account.

Choose another comparison ↗